Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis

被引：6

作者：

Dorn, Christoph ^{[1
]}

Petroff, David ^{[2
,3
]}

Kratzer, Alexander ^{[4
]}

Kees, Frieder ^{[5
]}

Kloft, Charlotte ^{[6
]}

Zeitlinger, Markus ^{[7
]}

Wrigge, Hermann ^{[3
,8
,9
]}

Simon, Philipp ^{[3
,10
]}

机构：

[1] Univ Regensburg, Inst Pharm, D-93040 Regensburg, Germany

[2] Univ Leipzig, Clin Trial Ctr, Leipzig, Germany

[3] Univ Leipzig, Integrated Res & Treatment Ctr IFB Adipos Dis, Leipzig, Germany

[4] Univ Hosp Regensburg, Hosp Pharm, Regensburg, Germany

[5] Univ Regensburg, Dept Pharmacol, Regensburg, Germany

[6] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Berlin, Germany

[7] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[8] Bergmannstrost Hosp Halle, Dept Anaesthesiol Intens Care & Emergency Med, Pain Therapy, Halle, Germany

[9] Martin Luther Univ Halle Wittenberg, Med Fac, Halle, Germany

[10] Univ Augsburg, Fac Med, Anaesthesiol & Operat Intens Care, Augsburg, Germany

来源：

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS | 2022年 / 47卷 / 05期

关键词：

CRITICALLY-ILL PATIENTS; PROTEIN-BINDING; PHARMACOKINETICS; INFECTIONS; PHARMACODYNAMICS; PLASMA; IMPACT; SERUM;

D O I：

10.1007/s13318-022-00789-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background and Objective Tigecycline, a broad-spectrum glycylcycline antibiotic, is approved for use at a fixed dose irrespective of body weight. However, its pharmacokinetics may be altered in obesity, which would impact on the antibiotic's effectiveness. The objective of this study was to investigate the plasma and subcutaneous tissue concentrations of tigecycline in obese patients compared with those in a non-obese control group. Methods Fifteen obese patients (one class II and 14 class III) undergoing bariatric surgery and 15 non-obese patients undergoing intra-abdominal surgery (mainly tumour resection) received a single dose of 50 or 100 mg tigecycline as an intravenous short infusion. Tigecycline concentrations were measured up to 8 h after dosing in plasma (total concentration), in ultrafiltrate of plasma (free concentration), and in microdialysate from subcutaneous tissue, respectively. Results In obese patients, total peak plasma concentration (1.31 +/- 0.50 vs 2.27 +/- 1.40 mg/L) and the area under the concentration-time curve from 0 to 8 h (AUC(8h,plasma): 2.15 +/- 0.42 vs 2.74 +/- 0.73 h.mg/L), as normalized to a 100 mg dose, were significantly lower compared with those of non-obese patients. No significant differences were observed regarding the free plasma concentration, as determined by ultrafiltration, or the corresponding AUC(8h) (fAUC(8h,plasma)). Concentrations in interstitial fluid (ISF) of subcutaneous tissue were lower than the free plasma concentrations in both groups, and they were lower in obese compared to non-obese patients: the AUC(8h) in ISF (AUC(8h,ISF)) was 0.51 +/- 0.22 h.mg/L in obese and 0.79 +/- 0.23 h.mg/L in non-obese patients, resulting in a relative tissue drug exposure (AUC(8h,ISF)/fAUC(8h,plasma)) of 0.38 +/- 0.19 and 0.63 +/- 0.24, respectively. Conclusion Following a single dose of tigecycline, concentrations in the ISF of subcutaneous adipose tissue are decreased in heavily obese subjects, calling for an increased loading dose.

引用

页码：749 / 755

页数：7

共 22 条

[1]

Alobaid A.S., Hites M., Lipman J., Taccone F.S., Roberts J.A., Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review, Int J Antimicrob Agents, 47, pp. 259-268, (2016)

[2]

Hanley M.J., Abernethy D.R., Greenblatt D.J., Effect of obesity on the pharmacokinetics of drugs in humans, Clin Pharmacokinet, 49, pp. 71-87, (2010)

[3]

Pai M.P., Antimicrobial dosing in specific populations and novel clinical methodologies: obesity, Clin Pharmacol Ther, 109, pp. 942-951, (2021)

[4]

Barbour A., Schmidt S., Ma B., Schiefelbein L., Rand K.H., Burkhardt O., Et al., Clinical pharmacokinetics and pharmacodynamics of tigecycline, Clin Pharmacokinet, 48, pp. 575-584, (2009)

[5]

(Tigecycline) for injection, for intravenous use, Prescribing information, (2021)

[6]

Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J., Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose, J Antimicrob Chemother, 58, pp. 1221-1229, (2006)

[7]

Bulik C.C., Wiskirchen D.E., Shepard A., Sutherland C.A., Kuti J.L., Nicolau D.P., Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis, Antimicrob Agents Chemother, 54, pp. 5209-5213, (2010)

[8]

Grupper M., Nicolau D.P., Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?, Curr Opin Infect Dis, 30, pp. 180-191, (2017)

[9]

Pai M.P., Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults, J Antimicrob Chemother, 69, pp. 190-199, (2014)

[10]

Ibrahim M.M., Abuelmatty A.M., Mohamed G.H., Nasr M.A., Hussein A.K., Ebaed M.E.D., Et al., Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights, Drug Design Dev Therapy., 12, pp. 4171-4179, (2018)

← 1 2 3 →